Percutaneous coronary interventions (PCI) for chronic total occlusion (CTO). Update 2022

Semlitsch T, Zipp C, Loder C
Record ID 32018002659
Authors' objectives: The therapeutic goal of percutaneous coronary intervention (PCI) in patients with chronic total occlusion (CTO) is to relieve symptoms and improve quality of life, avoid cardiac sequelae and more invasive coronary artery bypass grafting (CABG), and prolong life.
Authors' results and conclusions: The evidence (6 RCTs, n=1,911) indicates that PCI for CTO is more effective and as safe as optimal medical therapy (OMT) alone in terms of alleviating angina pectoris symptoms and improving quality of life. An adequate safety profile of PCI in CTO was further confirmed by four cohort studies (n=3,593). However, compared with CABG, the evidence from one RCT (n=460) and two cohort studies (n=3,025) is insufficient to draw conclusions on comparative efficacy and safety. There are currently five ongoing trials, none of which compare PCI with CABG in CTO.
Project Status: Completed
Year Published: 2022
URL for additional information:
English language abstract: An English language summary is available
Publication Type: Full HTA
Country: Austria
MeSH Terms
  • Percutaneous Coronary Intervention
  • Coronary Occlusion
  • Coronary Artery Disease
  • Cardiovascular Surgical Procedures
  • Angina Pectoris
  • Percutaneous coronary interventions
  • chronic total occlusion
  • coronary artery disease
Organisation Name: Austrian Institute for Health Technology Assessment
Contact Address: Garnisongasse 7/20, A-1090 Vienna, Austria
Contact Name:
Contact Email:
Copyright: HTA Austria - AIHTA GmbH
This is a bibliographic record of a published health technology assessment from a member of INAHTA or other HTA producer. No evaluation of the quality of this assessment has been made for the HTA database.